Trump Announces TrumpRx.gov: Discounted Pfizer Drugs to Be Sold Directly Online
USA tech news now : In a major policy move aimed at lowering the cost of prescription drugs, President Donald Trump announced Tuesday a new federal initiative, TrumpRx.gov, a government-run website that will allow Americans to buy Pfizer medicines at discounted rates. The announcement was made in the Oval Office, alongside Pfizer CEO Albert Bourla, CMS Administrator Mehmet Oz, and FDA Commissioner Martin Makary.
A Deal With Pfizer to Cut Drug Prices
The agreement between the Trump administration and Pfizer will enable patients to purchase medicines directly from the company through the TrumpRx.gov platform. According to Pfizer, prices for these drugs will average 50% lower than current list prices.
President Trump emphasized that this deal marks a turning point in how Americans pay for medicines compared to other developed nations.
“The American consumers have been subsidizing research and development for the entire planet,” Trump said. “They put all of that on us, and yet they were the beneficiaries too. So it’s been changed.”
Pfizer CEO Bourla added:
“I think today we are turning the tide, and we are reversing an unfair situation.”
How TrumpRx.gov Will Work
The TrumpRx website is expected to launch in 2026. Consumers will be redirected from the federal site to pharmaceutical companies’ direct-to-consumer portals to complete purchases.
Key points of the program:
- Discounted Pricing: Pfizer drugs available at an average 50% discount.
- Eligibility: The program is designed for patients not using insurance.
- Most-Favored-Nation Pricing: Pfizer has agreed to match U.S. drug prices with those in other developed countries.
Limitations and Concerns
While the administration celebrated the announcement, experts raised concerns over affordability. Since discounts are based on high list prices, patients without insurance could still face steep costs. In some cases, insured patients may still pay less at local pharmacies through co-pays and negotiated rates.
Additionally, specific terms of the deal remain confidential, and critics note the lack of transparency regarding how discounts were calculated.
Broader Push on Drug Price Reform
This move is part of the Trump administration’s broader initiative to align U.S. drug costs with international benchmarks, a concept known as most-favored-nation pricing. Health officials suggested that similar deals with other major pharmaceutical companies may follow.
Trump was joined at the press conference by NIH Director Jay Bhattacharya and Health and Human Services Secretary Robert F. Kennedy Jr., both of whom praised the initiative as a step toward addressing long-standing disparities in drug pricing.
What It Means for Patients
- Patients without insurance may benefit the most from TrumpRx discounts.
- Insured patients may find their pharmacy benefits still cheaper than direct online purchases.
- More pharmaceutical companies could join the platform in the future, potentially expanding access to lower-cost medications.
The TrumpRx initiative signals a shift in the U.S. drug pricing landscape, though its true impact will depend on execution, transparency, and whether other drugmakers sign similar agreements.
